Pre Seed · Biotech · Cambridge, United Kingdom · Founded 2021 · 1–10 employees
Vector Bioscience Cambridge is a biotechnology spin-out from the University of Cambridge developing a machine-learning-empowered drug delivery platform. The company designs programmable NanoShuttles based on highly porous metal-organic frameworks to encapsulate and transport therapeutic cargos directly to solid tumor microenvironments. This platform aims to maximize therapeutic efficacy while minimizing off-target systemic toxicity in hard-to-treat cancers like pancreatic and lung cancer. In March 2023, the startup secured a prominent €2,498,082 European Innovation Council Transition Challenge Grant to advance its siRNA delivery technology. Additionally, the company is collaborating with key industry players including AstraZeneca and the Milner Therapeutics Institute.
No open roles listed right now.